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ABSTRACT
Novel biomarkers predicting prostate cancer (PCa) aggressiveness and docetaxel 
therapy response of PCa patients are needed. In this study the correlation between 
nuclear Eg5-expression, PCa docetaxel response and PCa aggressiveness was 
assessed. Immunohistochemical staining for nuclear Eg5 was performed on 117 
archival specimens from 110 PCa patients treated with docetaxel between 2004 and 
2012. Samples were histologically categorized as positive/negative. 
Median follow-up time from diagnosis was 11.6 years. Nuclear Eg5-expression 
was significantly related to docetaxel response (p=0.036) in tissues acquired within 
three years before docetaxel initiation. Nuclear Eg5-expression was not related to 
Gleason-score (p=0.994). Survival of patients after docetaxel initiation did not differ 
based on nuclear Eg5-expression (p=0.540). Analyzing samples taken before hormonal 
therapy, overall survival and time to docetaxel use were significantly decreased in 
patients with nuclear Eg5-expressing tumors (p<0.01). Eg5-positive nuclei were found 
more frequently in T4-staged tumors (p=0.04), Gleason 8-10 tumors (p=0.08), and 
in metastasized tumors (p<0.01). Multivariate analyses indicated that nuclear Eg5-
expression may be an independent parameter for tumor aggressiveness. Limitations 
of a retrospective analysis apply.
In conclusion, nuclear Eg5-expression may be a predictive biomarker for 
docetaxel response in metastatic castrate-resistant PCa patients and a prognostic 
biomarker for hormone-naive PCa patients. Prospective validation studies are needed. 
INTRODUCTION
Metastatic castrate-resistant prostate cancer 
(mCRPC) is the second deadliest cancer in men in the 
Western world [1]. Primary first-line therapy for most 
mCRPC patients consists of the taxane docetaxel with 
prednisone [2;3], although various other mCRPC therapies 
have recently been introduced [4-8]. About 48% of patients 
initially respond to docetaxel therapy [2]; eventually all 
patients progress during or after docetaxel, usually within 
few months after their last cycle. As docetaxel inhibits 
depolarization of microtubules regardless of cell type [9], 
toxicities may be severe, such as polyneuropathy and bone 
marrow suppression [2]. To prevent or restrict unnecessary 
docetaxel use, and to determine the optimal treatment 
sequence for individual mCRPC patients [10], biomarkers 
predicting docetaxel response need to be identified and 
implemented in clinical practice [11]. 
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Table 1: Characteristics of mCRPC patients, their disease and treatment (n=110), and of the obtained tissue 
(n=117)
Patient Age
At time of prostate cancer diagnosis [median (range)] 64 (43-84)
At time of obtaining tissue [median (range)] 65 (43-86)
At time of start docetaxel [median (range)] 69 (46-87)
Disease characteristics (diagnostic imaging)
Gleason score [median (range)]
All patients 8 (4-10)
Hormone-naive patients 8 (4-10)
Number of metastatic lesions [number of patients (%)]
1 37 (33.6%)
2 49 (44.5%)
≥3 24 (21.8%)
Localization of metastases [number of patients (%)]
Lymph node 71 (64.5%)
Bone 106 (96.4%)
Liver 10 (9.1%)
Lung/pleura 16 (14.5%)
brain 1 (0.9%)
Treatment characteristics
Pretreatment [number of patients (%)]
Androgen-deprivation therapy 109 (99.1%)
Radical prostatectomy 15 (13.6%)
TUR-P 25 (22.7%)
Surgical castration 4 (3.6%)
Lymph node dissection 34 (30.9%)
Radiotherapy prostate 34 (30.9%)
Radiotherapy metastases 40 (36.4%)
Other 4 (3.6%)
Docetaxel treatment
# courses [median (range)] 1 (1-3)
# cycles [median (range)] 6 (1-20)
Best response [number of patients (%)]:
       progressive disease 22 (20.0%)
       stable disease 38 (34.5%)
       partial response 49 (44.5%)
Docetaxel rechallenge [number of patients (%)] 7 (6.4%)
Posttreatment [number of patients (%)] 91 (82.7%)
Cabazitaxel 16 (14.5%)
Abiraterone 30 (27.3%)
Enzalutamide 6 (5.5%)
Radiotherapy 47 (42.7%)
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We hypothesized that nuclear Eg5 (Kindle Spindle 
Protein/KSP/KIF11/kinesin-5) may be such a marker. Eg5 
separates spindle poles of a mitotic cell by crosslinking 
two antiparallel microtubules and moving to the plus-ends 
of both microtubules [12]. Due to its essential function in 
mitosis, multiple Eg5-inhibitors have been developed for 
anti-cancer therapy, such as ispinesib [13]. Two studies 
with ispinesib focused particularly on mCRPC patients, 
with ambiguous results. In a phase I study, six out of 
fourteen mCRPC patients had stable disease (SD) for 
≥18 weeks and one patient had a prostate-specific antigen 
(PSA)-decrease of >50% when ispinesib was combined 
with docetaxel in mCRPC patients [14]. In a phase II study 
in which ispinesib was administered as monotherapy, no 
responses were reported [15]. Twenty out of 21 patients 
had been treated with docetaxel prior to ispinesib. 
Immunohistochemistry analysis on archival tumor tissue 
from sixteen patients indicated that only one tumor 
stained positive for Eg5. It was concluded that ispinesib 
is not effective in primary prostate cancer (PCa) due to 
their low mitotic index, resulting in low Eg5 expression. 
However, considering their similar mechanism of action, 
an alternative explanation could be that cross-resistance 
occurs between docetaxel and Eg5-inhibitors.
Recent studies indicate that Eg5 may also play a 
role in intracellular transport in the cytoplasm, suggesting 
that Eg5-inhibitors may target Eg5 expressing non-mitotic 
cells too [16;17]. Xing et al. analyzed archival specimens 
from 80 patients with clinically localized PCa; half 
stained positive for Eg5, while benign prostate cells did 
not express Eg5 [18]. Considering the low mitotic index 
of PCa cells regardless of disease stage [19], these data 
suggest that Eg5 may indeed be expressed in non-mitotic 
PCa cells too [20]. 
Combining aforementioned findings [14;15;18], 
initial Eg5 expression of PCa may have been decreased 
once tumors have become docetaxel resistant. This led to 
our hypothesis that Eg5 may be a predictive marker for 
docetaxel response. Based on recent findings that patients 
with high Gleason-scores respond better to taxane-based 
therapy [21], we further hypothesize that Eg5 may be a 
prognostic marker for tumor aggressiveness and clinical 
outcome. 
RESULTS
Patient and tissue characteristics
In total, 117 samples were collected from 110 
mCRPC patients. These patients had been diagnosed 
with PCa between 1994 and 2011 and treated with 
docetaxel between July 15th, 2004 and December 
24th, 2012. Median time to follow-up from date of PCa 
diagnosis was 11.6 years (interquartile range 8.7-14.2 
years). Clinicopathological parameters are listed in Table 
1. Median age of patients when diagnosed with PCa 
was 64 years. Median Gleason-score of tumors was 8. 
Strontium-89 24 (21.8%)
Samarium-153 4 (3.6%)
Mitoxantrone 15 (13.6%)
Other 8 (7.3%)
Obtained pathological material
Type of material [number of samples (%)]
Biopsy 82 (70.0%)
TUR-P 24 (20.5%)
Radical prostatectomy 11 (9.4%)
Disease stage [number of samples (%)]
hormone-naive 87 (74.4%)
pre-docetaxel 112 (95.7%)
within three years of start docetaxel 61 (52.1%)
mCRPC post-docetaxel 5 (4.3%)
Survival
OS in years [median (IQR)] 4.8 (2.6-9.3)
Lost-to-follow-up [number of patients (%)] 18 (16.4%)
IQR, interquartile range; OS, overall survival; TUR-P, transurethral resection of the prostate
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About two-thirds of patients had ≥2 measured metastatic 
localizations when docetaxel was initiated. Of note, tumor 
imaging methods such as CT-scans were not performed 
in all patients, underestimating the number of metastatic 
lesions. All patients had been medically and/or surgically 
castrated. In general, patients had been heavily pretreated: 
patients had received up to five therapies before docetaxel 
therapy.
For immunohistochemistry, tonsil and healthy 
prostate tissue served as positive and negative controls, 
respectively (Fig. 1A-B). Obtained PCa tissue consisted 
primarily of biopsies (70.0%) (Table 1, supplementary 
Fig. 1). In the tumor samples, a clear distinction was 
observed between samples with nuclear Eg5 staining 
(5.1%), cytoplasmic Eg5 staining (19.7%), and samples 
staining positive for Eg5 in both compartments (63.2%), 
irrespective of the samples’ age (Fig. 1C-F). Samples 
were scored for nuclear or cytoplasm staining separately. 
Interobserver agreement of scoring was 98.1%.
Immunohistochemical Eg5 expression and 
docetaxel response
Eg5 expression varied in tumors from some patients 
who had multiple biopsies taken before docetaxel therapy. 
This variability always reflected a disappearance of 
Eg5 expression over time. It is unknown whether these 
changes occurred as the tumor evolved spontaneously 
or due to other therapies, such as androgen-deprivation 
therapy. Therefore, correlation between Eg5 expression 
and docetaxel response was evaluated for all patients 
(n=110) as well as for patients with samples taken 
within three years before docetaxel start (n=61). A clear 
trend was observed between nuclear Eg5 expression 
and a better response to docetaxel therapy (Fig. 2A, 
Figure 1: Immunohistochemical analysis of Eg5 
expression in human clinical samples. A. Positive control: a 
lymphatic tissue in a tonsil. B. Negative control: healthy prostate 
tissue. C. Prostate cancer (PCa) sample staining negative for 
Eg5. D. PCa sample with Eg5 expression in both the nuclei 
and cytoplasm. E. PCa sample with nuclear Eg5 expression. F. 
PCa sample with cytoplasmic Eg5 expression. G. Percentages 
indicate the frequencies samples with this subcellular staining 
pattern were found in our sample set (n=117).
Figure 2: Nuclear Eg5 expression and docetaxel response 
in mCRPC patients. A. Best disease response to docetaxel 
therapy in mCRPC patients, grouped by nuclear Eg5 expression 
of their tumor. Patients with stable disease (SD) were excluded 
from this analysis. The most recent PCa tissue before docetaxel 
therapy was analyzed from all patients (left) or only from patients 
who had tissue available obtained from the patient within three 
years before docetaxel therapy (right). In general, patients 
with nuclear Eg5 expression had a higher percentage of partial 
responses (PR). PD, progressive disease. B. Overall survival 
(OS) after docetaxel initiation. Patients were excluded when 
they only had PCa tissue available acquired more than three 
years before docetaxel therapy. Selected mCRPC patients were 
grouped based on nuclear Eg5 expression of their tumor. Median 
OS did not differ between patient groups, although initially there 
is more patient death in the group with Eg5-negative tumors.
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Supplementary Fig. 2). This correlation was significant in 
patients from whom tissue was taken within three years 
before docetaxel initiation: 71.9% of these patients with 
nuclear Eg5 expression had a PR versus 36.4% of patients 
without nuclear Eg5 expression (p=0.036). Conversely, 
cytoplasmic or any Eg5 expression did not predict 
docetaxel response (Supplementary Fig. 3).
As a previous report identified Gleason-scores as 
a predictive marker for docetaxel response, it was tested 
whether a correlation existed between Gleason-score 
and docetaxel response in our set of patient samples 
(Supplementary Table 1). Gleason-score was not related 
to docetaxel response, neither in all patients (p=0.343) nor 
in patients with tissue available in the three years before 
docetaxel initiation (p=0.884). Furthermore, Gleason-
score and nuclear Eg5 expression were not related in this 
latter subpopulation (p=0.994), suggesting that nuclear 
Eg5 expression was an independent marker of docetaxel 
response. 
We further explored the correlation between 
docetaxel response and Eg5 expression by investigating 
patients who had a PCa sample taken before and after 
docetaxel treatment. Only five patients matched these 
criteria. While cytoplasmic Eg5 expression did not alter 
in these patients, three out of four tumors with positive 
Eg5 nuclei before docetaxel therapy did not have nuclear 
Eg5 expression after docetaxel treatment (Supplementary 
Figure 4). These three patients had progressive disease 
upon discontinuation of docetaxel. On the other hand, 
the patient whose tumor expressed nuclear Eg5 pre- and 
post-docetaxel discontinued docetaxel therapy due to 
unacceptable toxicities. Despite the small patient number, 
these results suggested that loss of nuclear Eg5 expression 
may be related to docetaxel resistance.
Intriguingly, although patients with nuclear Eg5 
expression had a better response to docetaxel (Fig. 2A), 
no difference in OS, calculated from the start of docetaxel 
therapy to death, was evident between tumors based on 
nuclear Eg5 expression (p=0.540) (Fig. 2B). 
Figure 3: Tumor aggressiveness in mCRPC patients based on Eg5 expression. Patients were selected of whom PCa tissue acquired 
within three years (left) or three months (right) of diagnosis was available. Patients were divided in groups based on nuclear Eg5 expression. 
Median OS (top) and time to symptomatic mCRPC (bottom) were compared between patients groups. Patients with tumors that expressed 
Eg5 upon diagnosis, had a worse clinical outcome.
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Table 2: Multivariate analysis using the Cox-regression model exploring potential confounders for the correlation 
between nuclear Eg5 expression and tumor aggressiveness
All patients Hormone naive patients
Covariate OS [HR (95% CI)]
TTD [HR 
(95% CI)]
OS [HR 
(95% CI)]
TTD [HR 
(95% CI)]
Age 1.56 (0.95-2.54) 1.56 (1.00-2.42) 2.13 (1.13-4.02) 2.29 (1.31-3.98)
Gleason 1.48 (0.91-2.40) 1.45 (0.94-2.23) 1.76 (0.92-3.36) 1.78 (1.00-3.18)
Gleason <7 and ≥7 1.58 (0.95-2.63) 1.50 (0.95-2.38) 2.61 (1.35-5.07) 2.67 (1.50-4.75)
Gleason <8 and ≥8 1.48 (0.91-2.40) 1.46 (0.95-2.26) 1.84 (0.79-3.49) 1.93 (1.09-3.41)
T stage 1.75 (1.03-2.99) 1.59 (0.99-2.53) 2.56 (1.32-4.97) 2.64 (1.47-4.75)
Any metastases 1.52 (0.81-2.85) 1.28 (0.74-2.22) 2.25 (0.99-5.13) 1.97 (0.96-4.02)
Distant metastases 1.40 (0.79-2.49) 1.25 (0.75-2.08) 1.84 (0.87-3.87) 2.33 (1.14-4.79)
Number of metastases 1.64 (1.01-2.65) 1.59 (1.04-2.44) 2.61 (1.35-5.07) 2.67 (1.50-4.75)
CI, confidence interval; HR, hazard ratio; OS, overall survival; T stage, T stage according to TNM classification; TTD, time to 
docetaxel therapy.
Figure 4: Correlation between PCa characteristics and nuclear Eg5 expression in PCa patients. Patients were selected who had 
PCa tissue available within three years of PCa diagnosis. Tumors were divided in groups based on Gleason-score and TNM-classification 
upon diagnosis; the percentage of tumors with Eg5 expressing nuclei was compared. In general, PCa with nuclear Eg5 expression was more 
aggressive. Gl, Gleason; T, tumor stage according to TNM-classification; N, lymph node metastases (0, no metastases; 1, metastases); M, 
distant metastases (0, no metastases; 1, metastases), N1/M1, any metastases (lymph node and/or distant metastases).
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Immunohistochemical nuclear Eg5 expression 
and tumor aggressiveness
We evaluated whether tumors with nuclear Eg5 
expression behaved more aggressively. Analyzing samples 
from all 110 patients, patients with tumors with nuclear 
Eg5 expression had a significantly decreased OS (median 
6.6 versus 4.7 years, p=0.046) (Fig. 3A). Time from 
diagnosis to symptomatic mCRPC was also decreased 
(median 4.0 versus 2.8 years, p=0.037) (Fig. 3B). When 
selecting samples from hormone-naive patients (n=87), 
differences in OS and time to symptomatic mCRPC 
were even more pronounced (p=0.010 and p=0.006, 
respectively) (Fig. 3C-D). In this subset of patients, 
nuclear Eg5 expression was related to Gleason-score 
(p=0.014) and TNM classification (tumor stage, p=0.052; 
any metastases, p=0.007; distant metastases, p=0.021); no 
correlation existed between nuclear Eg5 expression and 
age (Fig. 4).
Multivariate analyses were performed to test 
whether the correlation between nuclear Eg5 expression 
and tumor aggressiveness (OS and time to symptomatic 
mCRPC) remained evident when correcting for potential 
confounding variables, such as Gleason-score (Table 2). 
When including all patients, addition of most covariates 
resulted in no statistically significant correlation between 
nuclear Eg5 expression and OS or time to symptomatic 
mCRPC. This included correction for age, while this 
variable was neither related to nuclear Eg5 expression nor 
to prognosis, suggesting the study was underpowered for 
such analyses. However, a trend towards positive nuclear 
Eg5 expression and aggressive tumors was evident. When 
assessing hormone-naive patients, a clearly positive 
trend existed between nuclear Eg5 expression and tumor 
aggressiveness regardless of the covariate added (hazard 
ratio >1.75), suggesting a potential independent prognostic 
value for nuclear Eg5 expression. The correlation between 
nuclear Eg5 expression and time to symptomatic mCRPC 
was significant in all subgroup analyses, except when 
metastases (N1 and/or M1) were added as a covariate 
(p=0.063). 
 DISCUSSION
Research has been ongoing identifying prognostic 
biomarkers and biomarkers predictive for therapy response 
in PCa with improved accuracy compared to established 
biomarkers such as serum PSA levels and Gleason-score, 
with some success [11]. Urokinase plasminogen activator 
and its inhibitor PAI-1, and Ki-67 have been identified 
as potential prognostic biomarkers of PCa [22;23]. 
Cytoplasmic localization of the androgen-receptor and 
increased blood serum levels of Macrophage Inhibitory 
Cytokine 1 (MIC-1) have been identified as a potential 
marker for PCa docetaxel response [24;25]. PCa tumors 
expressing class III beta-tubulin were relatively insensitive 
to PCa therapy: class III beta-tubulin expression resulted 
in faster recurrence after radical prostatectomies, a 
decreased docetaxel response and decreased survival [26]. 
Unfortunately, none of these markers are available yet for 
use in clinical practice [11]. Additional studies, such as the 
one we present here, are needed to identify a biomarker 
that is related to docetaxel response in PCa patients.
In the current study, we found that nuclear Eg5 
expression in PCa was associated with improved antitumor 
efficacy of docetaxel, independently of patient’s Gleason-
score. Furthermore, we identified nuclear Eg5 as a 
prognostic marker in hormone-naive PCa patients: patients 
whose tumor expressed nuclear Eg5 had a decreased 
median OS and progressed more rapidly to mCRPC. 
Similar findings were reported in non-small lung cancer 
patients: patients with Eg5 expressing tumors had a better 
response to chemotherapy, but a lower OS [27]. Similarly, 
Eg5 expression was related to worse clinical outcome in 
renal cell carcinoma patients [28].
Once docetaxel was initiated, survival of mCRPC 
patients was similar irrespective of nuclear Eg5 
expression. This may indicate that nuclear Eg5 expressing 
tumors initially respond well to docetaxel, resulting 
in decreased patient mortality. However, once these 
Eg5 expressing tumors progress, these tumors behave 
more aggressively, increasing patient death. This trend 
could indeed be derived from the survival curve (Fig. 
2B) and might explain why survival of patients with 
nuclear Eg5 expression is not increased after docetaxel 
treatment despite responding better to docetaxel therapy. 
Alternatively, other factors may have resulted in the 
similar survival curve, such as unequal patient and 
treatment characteristics between groups other than Eg5 
expression.
Nuclear Eg5 expression could provide a useful tool 
for clinical practice. Interobserver agreement between 
researchers was very high (98.1%), as no subjective 
degrees of positive staining (mild/moderate/strong) were 
used. Positive/negative scoring requires little interpretation 
from the pathologist. Determination of Eg5 expression at 
the time of diagnosis would be non-invasive, as tissue 
material is already acquired. Additional tissue sampling 
once the mCRPC stage has been reached could aid the 
physician in deciding when to initiate docetaxel therapy. 
Patients whose tumor expresses nuclear Eg5 may benefit 
by early docetaxel treatment; patients with Eg5-negative 
tumors may be recommended to initiate other therapies 
first, as docetaxel response is more limited. 
In the current study, a retrospective design was 
chosen, resulting in several limitations. FFPE PCa 
samples were collected from pathology archives; these 
samples were taken for diagnostic purposes (biopsies) and 
consisted of residual materials from surgical procedures 
such as TUR-P or radical prostatectomies. Therefore, 
the sample set we created was heterogeneous in origin. 
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However, on the contrary to other tumors such as breast 
cancer, only limited tissue material is available from PCa 
patients during their disease, as many patients have a 
prostatectomy early in their disease and primarily suffer 
from bone metastases, which are not easily accessible. 
Furthermore, additional tissue sampling is often not 
needed, as it currently would not influence further 
therapy decisions. Therefore, although our initial patient 
number was relatively large, only limited tissue material 
was available from patients shortly before docetaxel 
initiation. Hence all samples taken within three years of 
docetaxel initiation were collected for analysis. This led 
to a heterogeneous cohort of samples (both biopsies and 
residual surgical material), representing various stages of 
PCa disease. Furthermore, patients may have received 
various treatments between tissue sampling and docetaxel 
initiation. E.g., antiandrogen treatment significantly 
changed gene expression profiles of prostate cancer [29]. 
It is unknown whether such treatment specifically affects 
nuclear Eg5 expression. To overcome these challenges, a 
prospective study will be needed in which tissue will be 
collected shortly before docetaxel initiation to confirm the 
correlation between nuclear Eg5 expression and docetaxel 
response. However, such a study will need to overcome 
ethical and practical challenges as well. 
In addition, our patient population was 
underpowered for multivariate analyses in hormone-naive 
patients. Further prospective studies are warranted to 
validate whether nuclear Eg5 expression may serve as an 
independent prognostic biomarker. 
Previous studies found that PCa patients with 
aggressive tumors respond well to docetaxel, but also 
respond better to cabazitaxel, suggesting that aggressive 
tumors respond well to taxanes in general [30;31]. 
Therefore, additional studies are needed to assess whether 
Eg5 predicts response to cabazitaxel too. Finally, our 
study results suggest that loss of Eg5 expression may be 
related to docetaxel resistance. Although ispinesib had 
limited antitumor efficacy after docetaxel, our study and 
previous phase I findings suggest that ispinesib may be 
effective when administered before or concomitantly with 
docetaxel, when up to 70% of tumors express nuclear 
Eg5 [14]. However, combination therapy with docetaxel 
would need direct comparison to docetaxel monotherapy. 
Eg5-inhibitors may provide further clinical benefit 
when selecting mCRPC patients based on nuclear Eg5 
expression (personalized medicine).
In conclusion, nuclear Eg5 expressing PCa is 
aggressive, but responds well to docetaxel. Loss of 
nuclear Eg5 expression may be associated with docetaxel 
resistance. Determining nuclear Eg5 expression in PCa 
samples may aid to improve timing to initiate docetaxel 
therapy in individual PCa patients. Additional prospective 
studies are needed to confirm the predictive and prognostic 
value of nuclear Eg5.
METHODS
Collection of patient material and data
Formalin fixed and paraffin embedded (FFPE) 
human PCa samples (biopsies, transurethral resections 
of prostate (TUR-P) or radical prostatectomies), stored 
at room temperature, were collected from pathology 
archives of Leiden University Medical Center, Reinier de 
Graaf Gasthuis and Erasmus Medical Center Rotterdam. 
mCRPC patients who had pathological material available 
taken before docetaxel therapy were included. The study 
was carried out in accordance with the Dutch code of 
conduct for the secondary use of human tissues; informed 
consent was therefore not required when enough material 
remained to serve the patient’s and family’s needs [32]. 
Additional patient information was collected anonymously 
in a database. Approval was obtained from the Medical 
Ethics Board (METC) of Leiden University Medical 
Center (P12.219).
Immunohistochemistry
Samples (3µm sections) were stained for Eg5 using 
a polyclonal Anti-Eg5 antibody (1:1500, HPA006916, 
Sigma-Aldrich) on an automated immunohistochemistry 
stainer (Ventana Benchmark Ultra) (Fig. 1). This stainer 
utilized the ultraView Universal DAB Detection Kit 
(760-500, Ventana) for visualization of antibodies. 
The kit consisted of various enzyme labeled secondary 
antibodies that bind to primary antibodies; the complex 
was visualized with hydrogen peroxidase substrate and 
a 3.30-diaminobenzidine tetrahydrochloride (DAB) 
chromogen. For antigen retrieval, ULTRA CC1, an 
EDTA-Tris pH 8.4 solution, was used (950-224, Ventana). 
Representative images were taken at 20x10 under an 
Olympus BX41 microscope (Olympus Optical Co., Ltd.) 
from each slide using a colorview IIIu camera (Olympus), 
and analyzed with Cell^B imaging software (version 
2.4108-181207). If an image was representative for the 
whole slide, only one picture was taken; otherwise, three 
representative views were imaged per slide.
Data analysis
Images were examined and scored blindly and 
independently by two researchers (MDW, ESdM). A clear 
contrast between nuclear and cytoplasmic Eg5 staining 
was evident (Fig. 1). Recent studies have indicated 
that intracellular functions of Eg5 may differ based on 
its subcellular localization [17]; not all functions may 
be related to docetaxel response. Therefore, samples 
were scored for positive or negative staining of nuclei, 
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cytoplasm or any cellular compartment (nucleus and/or 
cytoplasm).
Samples were considered positive when in one high-
power field of view (20x10) at least four cancer cells were 
positive, regardless of intensity. This cut-off value ensured 
that random mitotic cells, infrequently found in the 
negative control too, were excluded. For analysis, average 
scores from both observers were calculated. If >50% of 
all scores per sample were positive for Eg5, the sample 
was considered Eg5-positive; otherwise it was considered 
Eg5-negative.
Clinical endpoints
Clinical endpoints used in this study include survival 
from docetaxel initiation, overall survival (OS), time to 
symptomatic mCRPC and best therapy response.
Time to symptomatic mCRPC was defined as time 
between PCa diagnosis and docetaxel initiation. OS was 
calculated as time between diagnosis and patient death. If 
patients had not died or were lost to follow-up, survival 
was censored at the day the patient was last known to be 
alive before July 20th, 2013.Tumor aggressiveness was 
based on OS, time to symptomatic mCRPC, Gleason-
score, and TNM-classification. Determination of best 
disease response (progressive disease, partial response) 
followed PCa working group guidelines as described 
previously, and could indicate PSA response and/
or response as viewed on imaging such as computer 
tomography [30;33].
Statistical analyses
Microsoft Excel 2003 was used for basic statistical 
analyses; student’s t-tests were conducted for comparisons. 
SPSS (version 20) was used for the Kaplan-Meier analyses 
of survival and time to symptomatic mCRPC; log-rank 
tests were used to compare these parameters between 
groups. Multivariate analyses were performed using the 
Cox-regression model. P-values ≤0.050 were considered 
statistically significant. 
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